Related references
Note: Only part of the references are listed.Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
Alfons J. M. van den Eertwegh et al.
LANCET ONCOLOGY (2012)
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
Ravi A. Madan et al.
LANCET ONCOLOGY (2012)
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination
Matteo Vergati et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
CTLA4 Blockade Induces Frequent Tumor Infiltration by Activated Lymphocytes Regardless of Clinical Responses in Humans
Rong Rong Huang et al.
CLINICAL CANCER RESEARCH (2011)
Prostate Cancer Immunotherapy
Kenneth F. May et al.
CLINICAL CANCER RESEARCH (2011)
Chemotherapy-Based Treatment for Castration-Resistant Prostate Cancer
Bostjan Seruga et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. De Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Immunomodulatory effects of cyclophosphamide and implementations for vaccine design
Antonella Sistigu et al.
SEMINARS IN IMMUNOPATHOLOGY (2011)
Cancer Statistics, 2010
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2010)
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer
James L. Gulley et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Two Distinct Mechanisms of Augmented Antitumor Activity by Modulation of Immunostimulatory/Inhibitory Signals
Jun Mitsui et al.
CLINICAL CANCER RESEARCH (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.
Philip W. Kantoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity
Nitya Jain et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Prostate cancer as a model for tumour immunotherapy
Charles G. Drake
NATURE REVIEWS IMMUNOLOGY (2010)
T(H)17 cells in tumour immunity and immunotherapy
Weiping Zou et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Cyclophosphamide Augments Antitumor Immunity: Studies in an Autochthonous Prostate Cancer Model
Satoshi Wada et al.
CANCER RESEARCH (2009)
Tumor Recognition and Self-Recognition Induce Distinct Transcriptional Profiles in Antigen-Specific CD4 T Cells
Derese Getnet et al.
JOURNAL OF IMMUNOLOGY (2009)
CTLA4 blockade increases Th17 cells in patients with metastatic melanoma
Erika von Euw et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2009)
CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion
Brian Kavanagh et al.
BLOOD (2008)
Phase 1/2 dose-escalation study of a GM-CSF-Secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer
Celestial S. Higano et al.
CANCER (2008)
LAG-3 regulates CD8+T cell accumulation and effector function in murine self- and tumor-tolerance systems
Joseph F. Grosso et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Live attenuated Listeria Monocytogenes effectively treats hepatic colorectal cancer Metastases and is strongly enhanced by depletion of regulatory T cells
Kiyoshi Yoshimura et al.
CANCER RESEARCH (2007)
Viral alteration of cellular translational machinery increases defective ribosomal products
Peter Berglund et al.
JOURNAL OF VIROLOGY (2007)
Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells
Monica V. Goldberg et al.
BLOOD (2007)
Tregs and rethinking cancer immunotherapy
Tyler J. Curiel
JOURNAL OF CLINICAL INVESTIGATION (2007)
Dendritic cells program non-immunogenic prostate-specific T cell responses beginning at early stages of prostate tumorigenesis
Marianne A. Mihalyo et al.
PROSTATE (2007)
CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells
Sergio A. Quezada et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen
CG Drake et al.
CANCER CELL (2005)
High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells
P Serafini et al.
CANCER RESEARCH (2004)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
IF Tannock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model
PJ Kaplan-Lefko et al.
PROSTATE (2003)
Successful therapy of metastatic cancer using tumor vaccines in mixed allogeneic bone marrow chimeras
L Luznik et al.
BLOOD (2003)
Autochthonous mouse models for prostate cancer: past, present and future
WJ Huss et al.
SEMINARS IN CANCER BIOLOGY (2001)
A novel technique for the fluorometric assessment of T lymphocyte antigen specific lysis
ME Sheehy et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2001)
Share Paper
